In addition to the differences in the methodology in these studies, variations in MPO levels have been reported in a variety of conditions, such as cancer, impaired leukocyte function in diabetes, cardiovascular diseases, endothelial dysfunctions, and pregnancy (based on glycemic control) and in patients taking fenofibrate drugs50–55. This evidence concerns the gene MPO and endothelial dysfunction.